TRIUMPH-4: retatrutide 12 mg, the Phase 3 leap of December 2025 TRIUMPH-4 is the first successful Phase 3 readout of the retatrutide program
For more tips on eating and drinking after your surgery, read Eating Well During Your Cancer Treatment
This is the dose studied in every FDA registration trial and the dose carried forward in long term extension work
For those with a low tolerance to tanning injections, consider micro-dosing 0.05 ml (1/20th of a syringe) for the first 3-4 days, or doubling the amount of water when mixing the solution to reduce side effects
How Weight-Loss Drugs Escaped the Diabetes Clinic GLP-1 receptor agonists were developed and approved for type 2 diabetes, with obesity approval following only after trials like STEP and SURMOUNT showed consistent, significant weight loss details we cover in Part 1 on how these drugs work
April 2025 Ozempic Lawsuits Update Shumperts complaint will be consolidated with similar claims brought throughout the federal court system, as part of a GLP-1 lawsuit multidistrict litigation (MDL), which is centralized in the Eastern District of Pennsylvania under U.S
